Graham Hetherington

Chair

Graham was appointed a Non-Executive Director in November 2019 and Chair of the Board in November 2020. He is also Chair of the Nomination Committee.

Graham brings substantial financial and industry experience to the Board having served as the Chief Financial Officer of two FTSE 100 companies.  He has a wide knowledge of international finance management and planning, including M&A and audit and risk management coupled with an in-depth understanding of the US market.

From 2016 to 2019, Graham was a Non-Executive Director of BTG plc, a global healthcare company, where he also served as Chair of the Audit Committee and, from 2017, as Senior Independent Director. Graham served as Chief Financial Officer of Shire PLC, a global pharmaceutical company, from 2008 until 2014, Chief Financial Officer of Bacardi and Company from 2007 to 2008 and Chief Financial Officer of Allied Domecq plc from 1999 to 2005.

Graham is a Fellow of the Chartered Institute of Management Accountants.

• Chair of the Nomination Committee
• Member of the Compliance, Ethics and Sustainability Committee
• Member of the Remuneration Committee

Mark Crossley

Chief Executive Officer

Mark was appointed Chief Executive Officer in June 2020.

Mark was appointed to the Board and as Chief Financial Officer in February 2017. In July 2019, he took on additional responsibilities and was appointed Chief Financial and Operations Officer with oversight of the finance, information technology, manufacturing, supply, quality and procurement functions. Mark joined the Company in 2012 as Global Finance Director with responsibilities for Finance, Information Systems and Procurement and served as Chief Strategy Officer from 2014 to 2017.

Prior to joining Indivior, Mark spent 13 years at Procter & Gamble in various finance leadership roles including Corporate Portfolio, Strategic and Business Planning (Female Beauty), as well as multiple roles in Corporate Treasury and its Baby Care division. He also enjoyed an eight-year career with various operational and staff assignments in the United States Coast Guard.

Mark graduated from the United States Coast Guard Academy with a BS in Management and Economics, and from Boston College with an MBA.

Peter Bains

Independent Non-Executive Director

Peter was appointed a Non-Executive Director in August 2019 and Chair of the Science Committee in January 2020.

Peter is currently Non-Executive Chair of ILC Therapeutics, a private UK-based biotechnology company and pioneer in the discovery and development of interferon drugs. He is also Group CEO of Biocon Limited, a biopharmaceutical company listed on the National Stock Exchange of India, and a Non-Executive Director of MiNA Therapeutics Limited.

Peter has over three decades of experience in the biotech and pharmaceutical industry, which included a 23-year career at GlaxoSmithKline, where he held numerous senior operational and strategic roles.  He also served as the Representative Executive Officer and Chief Executive Officer of Sosei Group Corporation, a Tokyo listed biotech company, and Chief Executive Officer of Syngene International, which he successfully took public on the Mumbai Exchanges in 2015.

Peter has a BSc Combined (Honours) in Physiology/Zoology from Sheffield University.

• Chair of the Science Committee
• Member of the Nomination Committee
• Member of the Remuneration Committee

Joe Ciaffoni

Independent Non-Executive Director

Joe was appointed a Non-Executive Director in December 2024. 

Joe previously served as President and CEO of Collegium Pharmaceutical. Given his prior experience at not only Collegium, but also Endo International (President of U.S. Branded Pharmaceuticals), Biogen (SVP, Global Specialty Medicines Group; U.S. Commercial) and Shionogi Inc. (COO), Joe has a demonstrated track record of launching successful products, optimizing commercial operations, and enhancing patient access to important therapies. 

Joe earned his MBA and BA at Rutgers University. 

• Member of the Nomination Committee 

Dr. Keith Humphreys

Independent Non-Executive Director

Keith was appointed a Non-Executive Director in November 2023.

Keith has over 30 years of experience in the field of clinical psychology and substance use disorders. He is an Esther Ting Memorial Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University and an Honorary Professor of Psychiatry at the Institute of Psychiatry, King’s College, London.  Keith was previously a Senior Policy Advisor in the White House Office of National Drug Control Policy in the Obama Administration.

Keith was awarded an OBE in September 2022 for his services to science and policy on addiction.

He holds a BA in Psychology from Michigan State University and an AM in Clinical/Community Psychology and PhD in Psychology from the University of Illinois.

• Member of the Compliance, Ethics & Sustainability Committee
• Member of the Nomination Committee
• Member of the Science Committee

Joanna Le Couilliard

Independent Non-Executive Director

Jo was appointed a Non-Executive Director in March 2021 and Chair of the Remuneration Committee in October 2023.

Jo is a healthcare industry veteran with 25 years’ healthcare management experience gained in Europe, the US and Asia. Much of her career has been in pharmaceuticals at GlaxoSmithKline where, amongst other roles, she headed the US vaccines business and Asia Pacific Pharmaceuticals business and led a program to modernize the commercial model. She was previously Chief Operating Officer at the BMI group of private hospitals in the UK.

Jo currently serves as a Non-Executive Director at the Italian listed pharmaceutical company, Recordati S.p.A., where she is also Chair of the Remuneration and Nominations Committee, and as an Independent Non-Executive Director of a joint venture company between GlobalData Plc and Inflexion. She has previously served as a Non-Executive Director and Chair of the Audit & Risk Committee at NIOX Group PLC, a Non-Executive Director and Chair of the Nomination Committee at Alliance Pharma plc and as a Non-Executive Director at Frimley Park NHS Foundation Trust in the UK, Cello Health PLC and at the Duke NUS Medical School in Singapore.

Jo is a Chartered Accountant holding an ACA from the Institute of Chartered Accountants and holds a Masters in Natural Sciences from the University of Cambridge.

• Chair of the Remuneration Committee
• Member of the Audit & Risk Committee
• Member of the Nomination Committee

Jerome Lande

Non-Executive Director

Jerome was appointed a Non-Executive Director in March 2021.

Jerome has over 20 years of experience as a professional investor, including substantial investing in medical device, pharmaceutical and healthcare services companies. He currently serves as Deputy Chief Investment Officer and Managing Partner at Scopia Capital Management. Jerome co-founded Coppersmith Capital Management, where he was managing partner and portfolio manager until it combined with Scopia in 2016. 

Prior to co-founding Coppersmith, Jerome was a partner of MCM Capital Management, LLC, the general partner of MMI Investments, LP, a small-cap investment fund founded in 1996 to employ private equity investing methodologies in public equities, and where Jerome oversaw research, trading and activism from 1998 to 2011. During that time, he was also associated with MCM’s private equity investments wherein he was directly involved with corporate development as well as equity growth.

Jerome is a member of the board of directors and Chair of the Strategy Committee of CONMED Corporation, a public global medical technology company. He also is a member of the board of directors of Itron Inc., a public global technology company that offers products and services on energy and water resource management. Jerome previously served as a Non-Executive Director of R&Q Insurance Holdings Ltd and as a member of the board of directors of Forest City Realty Trust, Inc., a public national real estate company. He holds a B.A. from Cornell University.

• Member of the Compliance, Ethics & Sustainability Committee

Ryan Preblick

Chief Financial Officer

Ryan was appointed Chief Financial Officer and Executive Director in November 2020, having served as Interim Financial Officer since June 2020.  

Ryan has been in a financial leadership capacity since joining Indivior in 2012 and prior to his appointment as Interim Chief Financial Officer in June 2020, he was Senior Vice President, Global Finance and Commercial Operations. This included overseeing all key financial management, analysis and reporting elements of the Group’s global business.

Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial aspects of the US business, the Group’s largest business, including management, planning, analysis and reporting, government pricing and managed care contracting operations. Ryan joined Indivior as US Commercial Controller.

Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Corporation (including Phillip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support.

Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond.

Robert Schriesheim

Independent Non-Executive Director

Robert was appointed a Non-Executive Director in December 2024.

Robert serves as Chairman of Truax Partners LLC and has extensive experience as a board member of public and private companies typically undergoing transformations while partnering with boards and institutional investors. In addition, he serves as an Adjunct Associate Professor of Finance with a focus on corporate governance at The University of Chicago Booth School of Business. He previously served as CFO of Sears Holdings, Hewitt Associates and Lawson Software and, earlier, held executive roles at seed venture firm ARCH Development Partners, LLC, Global TeleSystems, SBC Equity Partners, Ameritech, AC Nielsen and Brooke Group Ltd.  Robert has served as a director of Skyworks Solutions, Inc. since 2006 and Houlihan Lokey since 2015 where he is the Lead Independent Director.

Robert previously served on a number of public boards including Frontier Communications (as chairman of the Finance Committee overseeing its strategic redirection and Chapter 11 proceedings), NII Holdings, Forest City Reality Trust, Lawson Software, MSC Software and Dobson Communications.

Robert earned an AB in Chemistry from Princeton University and an MBA from the University of Chicago Booth School of Business. 

• Member of the Nomination Committee 

Barbara Ryan

Independent Non-Executive Director

Barbara was appointed a Non-Executive Director in June 2022.

Barbara was a Wall Street sell-side research analyst covering the US Large Cap Pharmaceutical Industry for more than 30 years before founding Barbara Ryan Advisors, a capital markets and communications firm, in 2012. Barbara has deep experience in equity and debt financings, M&A, valuation, SEC reporting, financial analysis and corporate strategy across a broad range of life sciences companies. 

Barbara is the founder of Fabulous Pharma Females, a non-profit organization whose mission is to advance women in the biopharma industry.  She is currently a Senior Advisor at EY (a part time role), a Board Member and Chair of the Compensation Committee at Azitra, Inc., a Non-Executive Director of INVO Bioscience, a Non-Executive Director and Chair of the Audit Committee at MiNK Therapeutics, and a Board Member of OcuTerra Therapeutics, Inc. and Safecor Health, LLC.

• Member of the Audit & Risk Committee
• Member of the Nomination Committee
• Member of the Remuneration Committee
• Member of the Science Committee

Mark Stejbach

Independent Non-Executive Director

Mark was appointed a Non-Executive Director in March 2021 and Chair of the Compliance, Ethics & Sustainability Committee in October 2023.

Mark has over 30 years of experience in biotech and pharmaceuticals, including senior roles in a broad range of commercial functions including marketing, sales, economic affairs, managed care and finance. From 2012 to 2018, Mark served as Senior Vice President and Chief Commercial Officer at Alkermes, plc, a publicly traded global biopharmaceutical company focused on development and commercialization of addiction and schizophrenia treatments.

Prior to his role at Alkermes, Mark served as the Chief Commercial Officer at Tengion, Inc. from 2008 to 2012, and he previously held senior positions at Merck and Biogen.  He served as a Non-Executive Director on the board of Flexion Therapeutics from 2016 to 2021.  Flexion marketed a “buy-and-bill” long-acting injectable for the treatment of osteoarthritis.  From 2019 to 2020, Mark served as Senior Commercial Advisor to EIP Pharma Inc., a private company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases.

Mark holds an MBA from the Wharton School, University of Pennsylvania and a BS in Mathematics from Virginia Tech.

• Chair of the Compliance, Ethics & Sustainability Committee
• Member of the Audit & Risk Committee
• Member of the Nomination Committee
• Member of the Science Committee

Juliet Thompson

Senior Independent Director

Juliet was appointed a Non-Executive Director in March 2021, as Chair of the Audit & Risk Committee in May 2021 and as Senior Independent Director in October 2023.

Juliet has over 30 years of finance, banking and board experience with significant focus in the healthcare sector. She is a proven FTSE 250 audit chair and a former investment banker who has spent her career advising pharmaceutical companies. She played a leading role in setting up Code Securities, which was later acquired by Nomura (becoming Nomura Code) but remained independent. At Nomura Code, Juliet was advising companies in the healthcare and clean tech sectors on their financing and strategic options. She worked on over 50 transactions including IPOs, secondary offerings, private placements and M&A. As Nomura Code was devolved, she joined Stifel with a team from Nomura Code to head up the life sciences and clean tech teams where she advised CEOs and CFOs in the healthcare sector.

Since retiring, Juliet has built a diverse portfolio; she is currently a Non-Executive Director and Chair of the Audit Committees of Novacyt S.A., Organox Limited and Angle PLC. She previously served on the Board of GI Dynamics, a Boston-based medical device company developing products for patients with type 2 diabetes and obesity.

Juliet holds a BSc in Economics from the University of Bristol and qualified as a Chartered Accountant and held an ACA from the Association of Chartered Certified Accountants.

• Chair of the Audit & Risk Committee
• Member of the Compliance, Ethics & Sustainability Committee
• Member of the Nomination Committee

Dr. David Wheadon

Independent Non-Executive Director

David was appointed a Non-Executive Director in June 2024.

David previously served as senior vice president of global regulatory affairs, patient safety, and quality assurance at AstraZeneca Plc from December 2014 to July 2019. Prior to that, he was executive vice president, research and advocacy at Juvenile Diabetes Research Foundation International Inc., from May 2013 to December 2014, and senior vice president, scientific and regulatory affairs at Pharmaceutical Research and Manufacturers of America (PhRMA), from January 2009 to May 2013. Prior to that he served as vice president, global pharmaceutical regulatory and medical science, and group vice president, global pharmaceutical regulatory affairs at Abbott Laboratories from 2005 to 2009 and held senior regulatory and clinical development leadership positions at GlaxoSmithKline Plc and Eli Lilly and Company.

David received his M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University.  He completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts.

David is a Non-Executive Independent Director of Sotera Health Company, Vaxart, Inc, and ConnectiveRx. He also serves as a member of the Board of Trustees of Mount Sinai Health System.

• Member of the Nomination Committee
• Member of the Remuneration Committee
• Member of the Science Committee

Mark Crossley

Chief Executive Officer

Mark was appointed Chief Executive Officer in June 2020.

Mark was appointed to the Board and as Chief Financial Officer in February 2017. In July 2019, he took on additional responsibilities and was appointed Chief Financial and Operations Officer with oversight of the finance, information technology, manufacturing, supply, quality and procurement functions. Mark joined the Company in 2012 as Global Finance Director with responsibilities for Finance, Information Systems and Procurement and served as Chief Strategy Officer from 2014 to 2017.

Prior to joining Indivior, Mark spent 13 years at Procter & Gamble in various finance leadership roles including Corporate Portfolio, Strategic and Business Planning (Female Beauty), as well as multiple roles in Corporate Treasury and its Baby Care division. He also enjoyed an eight-year career with various operational and staff assignments in the United States Coast Guard.

Mark graduated from the United States Coast Guard Academy with a BS in Management and Economics, and from Boston College with an MBA.

Ryan Preblick

Chief Financial Officer

Ryan was appointed Chief Financial Officer and Executive Director in November 2020, having served as Interim Financial Officer since June 2020.  

Ryan has been in a financial leadership capacity since joining Indivior in 2012 and prior to his appointment as Interim Chief Financial Officer in June 2020, he was Senior Vice President, Global Finance and Commercial Operations. This included overseeing all key financial management, analysis and reporting elements of the Group’s global business.

Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial aspects of the US business, the Group’s largest business, including management, planning, analysis and reporting, government pricing and managed care contracting operations. Ryan joined Indivior as US Commercial Controller.

Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Corporation (including Phillip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support.

Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond.

Jeffrey Burris

Chief Legal Officer

Jeff was appointed Chief Legal Officer in December 2021.  He brings over 25 years of extensive legal, life sciences and public company experience to Indivior, including over 15 years as the head of the legal function at various life sciences companies. 
Jeff joined Indivior from Arbor Pharmaceuticals where he was Vice President, General Counsel, Chief Compliance Officer and Secretary.  Prior to that he was Vice President, General Counsel, Chief Compliance Officer and Secretary at Alimera Sciences, a publicly traded pharmaceutical company, and Vice President, General Counsel and Chief Compliance Officer at CryoLife (now known as Artivion), a publicly traded biotechnology company.  
 
Jeff started his career in the corporate law group at Arnall Golden Gregory LLP focused on mergers, acquisitions, divestitures, contracting and licensing work.  He then moved in-house to Waste Management, where he was a Senior Counsel focused primarily on acquisitions and divestitures of Waste Management’s Southern Group.  

Jeff holds a BA in History and Economics from the University of Tennessee and a JD from The University of Chicago Law School.
 

Cynthia (Cindy) Cetani

Chief Integrity and Compliance Officer

In October 2018, Cindy was appointed as Chief Integrity & Compliance Officer for Indivior.  In this role, Cindy is responsible for leading the ongoing development, administration and evolution of the Indivior Global Integrity & Compliance Program, with maturity goals benchmarked against best practice standards.  Cindy brings to Indivior over 35 years of U.S. and global compliance leadership largely within the pharmaceutical industry, in addition to diverse cross-industry experience spanning managed care, life and health insurance.   The majority of her career has been dedicated to driving a culture of learning and integrity, and compliance program vision, while enabling innovation and patient-focused business results.

Cindy joined Indivior from Novartis Pharmaceuticals Corp (NPC) where she held roles of increasing responsibility over 15 years from 2003.  Initially focused on the U.S. pharmaceutical and oncology businesses, Cindy built a team of over 50 professionals and was responsible for harmonizing compliance across all the U.S. based Novartis divisions as Chief Compliance Officer NPC and U.S. Country Compliance Head.  In this role she led the development of a robust, effective compliance program and successful implementation of NPC’s 5-year Corporate Integrity Agreement with the Department of Health and Human Services Office of Inspector General.  As a member of the NPC Executive Committee, and the Global and International Compliance leadership teams, she co-led strategic priority development and execution.   Cindy then took on an international role as Head of Compliance Operations, Group Integrity & Compliance at the Novartis headquarters in Basel, Switzerland.  There, she led the implementation of the global compliance program evolution and established central operations support across all global divisions and 160 countries, while leading the compliance analytics approach for effective risk management and program measurement.  Before joining NPC, Cindy was Director of Operations, Managed Markets at Pharmacia, led Advertising Compliance for Prudential Healthcare, and held various senior management roles at US Life Insurance and Mutual Benefit Life Insurance companies.

Cindy is  Leadership Professional in Ethics & Compliance (LPEC) certified, National Association of Corporate Directors (NACD.DC ®) certified, and holds a Bachelor of Science, Commerce, Finance – Magna Cum Laude from Rider College, Lawrenceville, New Jersey.

Angela Colon-Mahoney

Chief Human Resources Officer

Angela was appointed Chief Human Resources Officer with effect from September 2024.  She is an accomplished senior executive with over two decades of experience within and beyond human resources and operations through multiple executive and leadership positions across prominent organizations such as Otsuka Pharmaceutical, The Estee Lauder Companies, Tyco International, Mercer Delta, and Unilever. Angela is recognized for driving strategic initiatives to enhance organizational effectiveness, talent development and business performance.

Most recently, Angela was the Chief Human Resources Officer at Otsuka Pharmaceuticals leading the development and execution of Otsuka’s human resources strategy and business services in support of the company’s efforts to deliver next generation solutions to people. During her tenure she led multiple executive and organization transformations, mergers and divestitures, and implemented a highly effective CEO and executive succession program. Under Angela, Otsuka received recognition as a Great Place To Work, leader in employee mental health benefits, as well as diversity and inclusion, in addition to being recognized as one of Forbes’ Magazine’s “Best Places To Work.”

Angela has been recognized as a strategic leader in behavioral health initiatives whose impact has spanned industries, exemplifying her commitment to fostering inclusive workplaces and driving positive societal change. She continues to shape the conversation on important topics through her insights and contributions navigating the critical intersection of business, leadership, and human capital management.

Angela holds a Bachelor of Arts in Psychology from Saint John's University and a Master of Science in Organization Change Management from The New School University, both in New York.  

Jon Fogle

Chief Human Resources Officer

In October 2014, Jon was appointed Chief Human Resource Officer for Indivior. Jon joined Reckitt Benckiser Pharmaceuticals (RBP) as Human Resources Director for the US in 2007. In 2010, he was promoted to Global Human Resources Director. Under his leadership, the company has grown rapidly from just over 200 employees in three countries to more than 1,000 employees in more than 10 countries. Working with the entire leadership team, Jon has fostered a strong commitment to developing both Indivior’s culture and talent.

Prior to joining RBP, Jon was Senior Vice President of Human Resources, North America for Capmark Finance (formerly GMAC Commercial Mortgage).

Jon holds a BS in psychology from Ursinus College and is a SHRM Senior Certified Professional.

Jon will be retiring from Indivior in 2025.

Christian Heidbreder

Chief Scientific Officer

Christian combines 30 years’ experience in the neurosciences spanning the academic, governmental, and industrial sectors across Europe and the US. He authored and co-authored over 450 peer-reviewed scientific publications, reviews, and published conference proceedings with more than 10,000 citations.

For 10 years prior to crossing into industry, Christian made a mark in the halls of Academia at the University of Louvain (UCL) in Belgium, at the National Institute on Drug Abuse (NIDA) in Baltimore, and at the Swiss Federal Institute of Technology in Zürich (ETH) in Switzerland.

For the last 20 years, Christian held positions of increasing responsibility at SmithKline-Beecham’s Neuroscience Department in the UK, GSK’s R&D Centre of Excellence for Drug Discovery in Psychiatry in Italy, Altria’s Health Sciences Department in the US, and Reckitt Benckiser in the US and the UK. Following the demerger of the Pharmaceuticals component of Reckitt Benckiser, Christian joined Indivior as Chief Scientific Officer to provide strategic global leadership for worldwide R&D and Medical Affairs operations and drive the development of new pharmacotherapies in the area of addiction and related co-morbidities.

Christian holds BA, MA, and PhD degrees from the University of Louvain and a Certificate in Strategic Innovation from the Wharton Business School. He is an Affiliate Professor in the Department of Pharmacology & Toxicology of the Virginia Commonwealth University School of Medicine since 2010. He is a Governance Fellow of the National Association of Corporate Directors (NACD) since 2014. Christian also served as a member of the National Advisory Council on Drug Abuse (NACDA) (2018-2023) and as a member of the Helping to End Addiction Long-term (HEAL) Multi-Disciplinary Working Group (MDWG) (2018-2023), which focuses on the National Institutes of Health (NIH) efforts to speed scientific solutions to stem the opioid crisis.

Kathryn Hudson

Company Secretary

Kathryn is a Fellow of the Chartered Governance Institute with more than twenty years’ experience gained across a wide variety of industries and sectors in FTSE 100 and FTSE 250 listed companies.

Prior to joining Indivior, Kathryn was Company Secretary of Kingfisher plc, one of Europe’s largest retailers and Deputy Company Secretary of Burberry Group plc.

Vishal Kalia

Chief Impact and Strategy Officer

Vishal Kalia has a proven track record for long-term organizational growth and strategic communications excellence. He brings to our Executive Committee over two decades of diverse global pharmaceutical experience. 

He started with Indivior in 2016 as the U.S. Marketing Head and was subsequently appointed as the business unit head for U.S. Addiction Sciences. He was later promoted to Senior Vice President, U.S. Commercial Access. Vishal successfully developed and implemented the SUBLOCADE launch strategy in the U.S. He led the team through the creation and execution of strategies for Organized Health Systems, the Criminal Justice System and transformed Indivior from a retail-focused organization to one with a specialty focus. In March 2023, he was appointed to the position of Chief Strategy Officer, where he continued to play a pivotal role in shaping the company's strategic direction. Shortly after the appointment, he took on additional responsibilities and became Chief Impact and Strategy Officer.

Prior to his tenure at Indivior, he spent over a decade at Reckitt Benckiser, where he held global senior leadership roles, building teams and businesses across Europe, North America, and Asia. His time at Reckitt Benckiser was marked by numerous product launches, the formulation of long-term plans for diverse categories, and the creation of award-wining communications campaigns. He has launched and oversaw several multibillion-dollar brands globally.

He holds a Bachelor's degree in Commerce and Accountancy from DAVV University in India and a Master's degree in International Marketing Management from Leeds University in the U.K.

Richard Simkin

Chief Commercial Officer

Richard has over 20 years of global commercial business experience. He began his career with Reckitt & Colman in 1987 and has held various roles in operations, sales and marketing with increasing responsibility. In addition to his Commercial responsibilities, he took over responsibility for the Global Strategy function in 2017 and managed until 2023 when his role was divided to allow for more focus and growth in Commercial and Strategy.

Prior to his role with RBP, Richard held the position of Global Category Director for one of the core categories within the RB Group where he was responsible for driving strategy and new product development. In addition, he has extensive experience in the healthcare markets ranging from over the counter to prescription products in multiple categories and countries. Richard has also held a number of general manager positions within the RB Group, most recently as General Manager, Portugal in 2008.

In 2012 Richard was appointed President, North America of RBP and moved to the US where he currently leads the Commercial organizations in North America, Europe Middle East Africa, and AustralAsia in successfully navigating the introduction of market competition along with the preparation of pre-launch activities related to the product pipeline.

Richard holds an MBA from the University of Lincoln (formerly known as the University of Lincolnshire and Humberside).

Hillel West

Chief Manufacturing and Supply Officer

In February 2020, Hillel was appointed Chief Manufacturing and Supply Officer at Indivior.

Hillel brings to Indivior more than 25 years of experience in Operations Management, Strategy and Business Development across US, Europe, Asia-Pacific and emerging markets.
 

He joined Indivior from Teva Pharmaceuticals where he held roles of increasing responsibility over his 14-year tenure including Head of Specialty Medicines Supply, Head of Global Supply Chain and Operations Strategy, and VP – Integration and Separation Management. Previously, he was a senior director at PwC Management Consulting for 9 years in New York, Israel and Czech Republic, partnering with a number of US Fortune 500 CPG, Food and Pharma manufacturers leading engagements in Supply Chain strategy, Organizational and Process transformation.
 

Hillel holds a Bachelor of Chemical Engineering (Hons) from Monash University, Australia and an MBA from Columbia University, NY.